FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/12/2026
Back to search
Official data from USPTO
S-OPTICHARGE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
08/12/2026
Trademark type
Combined
Nice classes
1, 40, 42
Filing date
01/10/2025
Registration date
05/12/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/12/2026
Last transaction
08/12/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
03
Owner location
KR
Examiner
BLAZICH, JOAN MICHELE
Law office
N40
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "S-OPTICHARGE".
Holders and representatives
Holders
Samsung Biologics Co., Ltd.
Representatives
Brian P. Gregg McNees Wallace & Nurick
Technical classification
Nice Classes
Class 1Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Preparations being industrial chemicals for gene recombination for scientific or laboratory purposes; chemical reagents for genetic identity testing for non-medical purposes; chemical reagents for use in genetic research; chemical reagentsother than for medical or veterinary purposes; synthetic gene for research other than for medical purposeschemical reagents for use in genetic research; biological preparations for use in biotechnology being use in industry and science other than for medical purposes; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for use in industry; biological preparation for use in cell cultures other than for medical or veterinary use; biological tissue culturesother than for medical or veterinary purposes; reagents for scientific and research use for use in scientific apparatus for chemical or biological analysis; stem cells other than for medical or veterinary purposes; stem cells for research purposes; stem cells for scientific purposes; cell growth media for growing cells for use in scientific research; cells for scientific or research laboratory purposes
Class 40
Custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; custom manufacture of cell lines for manufacturing biopharmaceuticals; chemical treatment of liquids; processing of medicinal materials; custom manufacture of pharmaceuticals; processing of pharmaceutical preparations; preservation of pharmaceuticals; processing of pharmaceuticals; custom manufacture of specific antibody-binding glycosylated drugs; processing of chemicals
Class 42
Scientific laboratory services for high-efficiency glycan analysis; culturing of cells for others for scientific research purposes; scientific research; biological research and analysis relating to glycosylation profiles; multiple nucleic acid scientific analysis; scientific protein analysis; scientific toxicity analysis; analysis in the field of molecular biology; development of biotechnology; biotechnological research; biological analysis; biological research; research of biologics; biochemical analysis; biochemical research; food research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research on the subject of pharmaceuticals; pharmaceutical product evaluation; clinical research in the field of medicine; scientific analysis services for assessing the efficiency of pharmaceuticals; scientific research in the field of genetics and genetic engineering; animal genetic research; computer programming in the medical field; medical research laboratories; computer software technical support services relating to the management of medical image datatroubleshooting of computer software problems; medicine research; scientific analysis and evaluation of medical product development; providing scientific information on the testinginspection and research of medical products; evaluating of clinical trial progressquality control for others; conducting clinical trials for others
Publications
History of USPTO decisions and trademark events.
23 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/05/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
08/05/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/12/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
05/12/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/24/2026
PUBO
PUBLISHED FOR OPPOSITION
03/24/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/18/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/27/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/23/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/23/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/23/2026
PETG
PETITION TO REVIVE-GRANTED
02/23/2026
PROA
TEAS PETITION TO REVIVE RECEIVED
02/23/2026
RFNT
REFUSAL PROCESSED BY IB
08/29/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/14/2025
RFRR
REFUSAL PROCESSED BY MPU
08/13/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/02/2025
CNRT
NON-FINAL ACTION WRITTEN
07/01/2025
DOCK
ASSIGNED TO EXAMINER
06/18/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/09/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/09/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/06/2025
Continuous trademark protection
Get notified about every new filing that threatens S-OPTICHARGE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.